In 198 patients with untreated intermediate/poor-risk advanced clear-cell RCC, tobemstomig plus axitinib (± tiragolumab) gave more grade 3–4 AEs (62.1%, 67.7% vs 56.7%) and no clear efficacy gain over pembrolizumab–axitinib; stopped after interim futility analysis.
RCTn = 198
Rini et al. A randomised, open-label, phase II study of tobemstomig combinations in patients with previously untreated advanced clear-cell renal cell carcinoma